Herpes zoster virus infection.
OBJECTIVE
The virology, pathophysiology, and treatment of the varicella zoster virus (VZV) have been investigated for many years now. Infection with VZV has different ramifications for people of different ages and immune status. The various aspects of VZV disease make it difficult to treat. Selected aspects of VZV disease that pertain to ocular disease are presented.


RESULTS
The risk factors for VZV disease in the different age spectrums and with concomitant immunodeficiencies have been further clarified. Studies suggest that the VZV may persist for prolonged periods on the cornea after herpes zoster ophthalmicus (HZO). Herpes Simplex Virus (HSV) or VZV may cause many cases of idiopathic uveitis with sectoral iris atrophy. The different patterns of retinal disease caused by VZV may relate to the immune status. Systemic antiviral medications for herpes zoster should be instituted within 72 hours of the rash but could be used later. Systemic antivirals combined with systemic corticosteroids improve the early quality of life in HZ patients. Postherpetic neuralgia is not prevented by early systemic antivirals or corticosteroids. Present systemic antivirals are all effective, but Famvir offers the best dosing schedule. The VZV vaccine is effective but there are some issues that suggest the need for a different vaccination regimen.


CONCLUSIONS
Further research must be performed on the clinical and therapeutic aspects of the VZV disease. Although both the vaccine and systemic antivirals have brought tremendous improvements, the disease persists. Therapy lessens but does not eliminate many of the complications. The disease may manifest in unpredictable patterns in this era of vaccination.
Liesegang
Thomas J
TJ
Mayo Clinic Medical School, Jacksonville, Florida, USA. tliesegang@mayo.edu
D000998:Antiviral Agents / Q000627:therapeutic use; D003315:Cornea / Q000821:virology; D006562:Herpes Zoster / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006563:Herpes Zoster Ophthalmicus / Q000150:complications; D014645:Herpesvirus 3, Human / Q000302:isolation & purification; D022283:Herpesvirus Vaccines / Q000627:therapeutic use; D006801:Humans; D012164:Retinal Diseases / Q000821:virology; D012307:Risk Factors; D013997:Time Factors; D014605:Uveitis / Q000821:virology
D000998:Antiviral Agents; D022283:Herpesvirus Vaccines